Etalocib
Names | |
---|---|
IUPAC name
2-(3-{3-[(5-ethyl-4'-fluoro-2-hydroxybiphenyl-4-yl)oxy]propoxy}-2-propylphenoxy)benzoic acid | |
Other names
LY293111 VML 295 | |
Identifiers | |
161172-51-6 | |
3D model (Jmol) | Interactive image |
ChEMBL | ChEMBL329123 |
ChemSpider | 154905 |
2948 | |
KEGG | D04074 |
PubChem | 177941 |
UNII | THY6RIW44R |
| |
| |
Properties | |
C33H33FO6 | |
Molar mass | 544.62 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
verify (what is ?) | |
Infobox references | |
Etalocib is a drug under development for the treatment of various types of cancer, for example non-small-cell lung carcinoma[1] and pancreatic cancer. It acts as a leukotriene B4 receptor antagonist and a PPARγ agonist.[2]
References
- ↑ Jänne, P. A.; Paz-Ares, L; Oh, Y; Eschbach, C; Hirsh, V; Enas, N; Brail, L; von Pawel, J (2014). "Randomized, double-blind, phase II trial comparing gemcitabine-cisplatin plus the LTB4 antagonist LY293111 versus gemcitabine-cisplatin plus placebo in first-line non-small-cell lung cancer". Journal of Thoracic Oncology. 9 (1): 126–31. doi:10.1097/JTO.0000000000000037. PMID 24346102.
- ↑ Adrian, T. E.; Hennig, R; Friess, H; Ding, X (2008). "The Role of PPARgamma Receptors and Leukotriene B(4) Receptors in Mediating the Effects of LY293111 in Pancreatic Cancer". PPAR Research. 2008: 827096. doi:10.1155/2008/827096. PMC 2631651. PMID 19190780.
This article is issued from Wikipedia - version of the 7/17/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.